Literature DB >> 12475091

Anticholinergic burden and the risk of falls among elderly psychiatric inpatients: a 4-year case-control study.

Dov Aizenberg1, Mayanit Sigler, Abraham Weizman, Yoram Barak.   

Abstract

OBJECTIVE: Falls are an everyday risk for the elderly and their etiology is multifactorial. Because there are little data focusing on falls among elderly psychiatric inpatients, we aimed to retrospectively assess the characteristics of inpatients that had sustained a fall during hospitalization.
METHODS: Over 4 years, all adverse-event reports of falls were reviewed. Inclusion criteria were age >65 years and intact cognition. The control group consisted of the previous and next admission of an elderly patient to the same ward. Anticholinergic score was calculated for each patient.
RESULTS: Of 414 admissions of elderly patients, 34 (8.2%) patients had had a fall. The control group (n = 68) did not differ in mean age, distribution of diagnoses, or use of benzodiazepines, antidepressants, or antipsychotics. Two variables were significantly associated with falls: female gender (68% vs. 39%, p < .05) and anticholinergic burden score (ABS) (mean: 3.7 vs. 2.1, p < .05).
CONCLUSIONS: Our results support reported findings of higher rates of falls among elderly women and suggest that ABS may be a risk factor for falls.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12475091     DOI: 10.1017/s1041610202008505

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN: 1041-6102            Impact factor:   3.878


  41 in total

1.  Associations between drug burden index and mortality in older people in residential aged care facilities.

Authors:  Nicholas M Wilson; Sarah N Hilmer; Lyn M March; Jian Sheng Chen; Danijela Gnjidic; Rebecca S Mason; Ian D Cameron; Philip N Sambrook
Journal:  Drugs Aging       Date:  2012-02-01       Impact factor: 3.923

Review 2.  Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients.

Authors:  Martin Klietz; Stephan Greten; Florian Wegner; Günter U Höglinger
Journal:  Drugs Aging       Date:  2019-06       Impact factor: 3.923

3.  Anticholinergics and central nervous system effects: are we confused?

Authors:  David R Staskin; Edward Zoltan
Journal:  Rev Urol       Date:  2007

4.  Risk of Mortality Associated with Non-selective Antimuscarinic medications in Older Adults with Dementia: a Retrospective Study.

Authors:  Nandita Kachru; Holly M Holmes; Michael L Johnson; Hua Chen; Rajender R Aparasu
Journal:  J Gen Intern Med       Date:  2020-02-05       Impact factor: 5.128

5.  Managing anticholinergic side effects.

Authors:  Joseph A Lieberman
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

6.  Inappropriate prescribing for the elderly--a modern epidemic?

Authors:  Gunhild Nyborg; Jørund Straand; Mette Brekke
Journal:  Eur J Clin Pharmacol       Date:  2012-02-15       Impact factor: 2.953

7.  Co-treatment with rivastigmine and idalopirdine reduces the propensity for falls in a rat model of falls in Parkinson's disease.

Authors:  Ajeesh Koshy Cherian; Aaron Kucinski; Ryan Wu; Inge E M de Jong; Martin Sarter
Journal:  Psychopharmacology (Berl)       Date:  2019-01-04       Impact factor: 4.530

Review 8.  Where attention falls: Increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function.

Authors:  Martin Sarter; Roger L Albin; Aaron Kucinski; Cindy Lustig
Journal:  Exp Neurol       Date:  2014-05-05       Impact factor: 5.330

9.  Effect of Anticholinergic Medications on Falls, Fracture Risk, and Bone Mineral Density Over a 10-Year Period.

Authors:  Lisa-Ann Fraser; Jonathan D Adachi; William D Leslie; David Goltzman; Robert Josse; Jerilynn Prior; Stephanie Kaiser; Nancy Kreiger; Christopher S Kovacs; Tassos P Anastassiades; Alexandra Papaioannou
Journal:  Ann Pharmacother       Date:  2014-05-09       Impact factor: 3.154

Review 10.  Pharmacological treatment in Parkinson's disease: Effects on gait.

Authors:  Katrijn Smulders; Marian L Dale; Patricia Carlson-Kuhta; John G Nutt; Fay B Horak
Journal:  Parkinsonism Relat Disord       Date:  2016-07-17       Impact factor: 4.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.